Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Not recommended

145 appraisals, newest first, page 2 of 2
AppraisalMedicine pageNICE recommendationPublishedStatus
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
NICE TA227
ErlotinibNot recommended29 Jun 2011Current
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
NICE TA223
Cilostazol, PentoxifyllineRecommended Not recommended25 May 2011Current
Trabectedin for the treatment of relapsed ovarian cancer
NICE TA222
TrabectedinNot recommended27 Apr 2011Replaced by TA389
Everolimus for the second-line treatment of advanced renal cell carcinoma
NICE TA219
EverolimusNot recommended19 Apr 2011Replaced by TA432
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
NICE TA214
BevacizumabNot recommended23 Feb 2011Current
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
NICE TA212
BevacizumabNot recommended15 Dec 2010Current
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
NICE TA209
ImatinibNot recommended24 Nov 2010Current
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
NICE TA205
EltrombopagNot recommended27 Oct 2010Current
Liraglutide for the treatment of type 2 diabetes mellitus
NICE TA203
LiraglutideRecommended Optimised Not recommended27 Oct 2010
Updated 1 Dec 2014
Current
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
NICE TA202
OfatumumabNot recommended27 Oct 2010Withdrawn
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11
NICE TA201
OmalizumabNot recommended27 Oct 2010Replaced by TA278
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA196
ImatinibNot recommended25 Aug 2010Replaced by TA326
Sorafenib for the treatment of advanced hepatocellular carcinoma
NICE TA189
SorafenibNot recommended26 May 2010Replaced by TA474
Topotecan for the treatment of relapsed small-cell lung cancer
NICE TA184
TopotecanRecommended Not recommended25 Nov 2009Current
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
NICE TA178
Bevacizumab, Sorafenib, Temsirolimus, SunitinibNot recommended26 Aug 2009Current
Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
NICE TA172
CetuximabNot recommended24 Jun 2009Current
Amantadine, oseltamivir and zanamivir for the treatment of influenza
NICE TA168
Amantadine, OseltamivirRecommended Not recommended25 Feb 2009Current
Cochlear implants for children and adults with severe to profound deafness
NICE TA166
—Recommended Optimised Not recommended28 Jan 2009Current
Erlotinib for the treatment of non-small-cell lung cancer
NICE TA162
ErlotinibRecommended Not recommended26 Nov 2008
Updated 1 Dec 2012
Current
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
NICE TA160
Alendronate, EtidronateOptimised Not recommended27 Oct 2008
Updated 7 Feb 2018
Current
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
NICE TA158
Amantadine, OseltamivirNot recommended Recommended24 Sep 2008Current
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
NICE TA155
RanibizumabRecommended Not recommended27 Aug 2008
Updated 20 May 2024
Current
Telbivudine for the treatment of chronic hepatitis B
NICE TA154
—Not recommended27 Aug 2008Current
Adalimumab, etanercept and infliximab for ankylosing spondylitis
NICE TA143
Adalimumab, Etanercept, InfliximabRecommended Not recommended28 May 2008Replaced by TA383
Abatacept for the treatment of rheumatoid arthritis
NICE TA141
AbataceptNot recommended23 Apr 2008Current
Infliximab for subacute manifestations of ulcerative colitis
NICE TA140
InfliximabNot recommended23 Apr 2008Replaced by TA329
Structural neuroimaging in first-episode psychosis
NICE TA136
—Not recommended27 Feb 2008Current
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
NICE TA130
Adalimumab, Etanercept, InfliximabNot recommended Optimised22 Oct 2007Replaced by TA375
Pemetrexed for the treatment of non-small-cell lung cancer
NICE TA124
PemetrexedNot recommended22 Aug 2007Current
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
NICE TA119
FludarabineNot recommended28 Feb 2007Current
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
NICE TA118
Bevacizumab, CetuximabNot recommended24 Jan 2007
Updated 1 Jan 2012
Current
Paclitaxel for the adjuvant treatment of early node-positive breast cancer
NICE TA108
PaclitaxelNot recommended27 Sep 2006Current
Immunosuppressive therapy for renal transplantation in children and adolescents
NICE TA99
Basiliximab, Sirolimus, Tacrolimus, Mycophenolate MofetilNot recommended Recommended Optimised26 Apr 2006Current
Computerised cognitive behaviour therapy for depression and anxiety
NICE TA97
—Not recommended Recommended Only in research22 Feb 2006Withdrawn
The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza
NICE TA67
Amantadine, OseltamivirNot recommended Recommended24 Sep 2003Current
Flu treatment - zanamivir, amantadine and oseltamivir
NICE TA58
Amantadine, OseltamivirNot recommended Recommended26 Feb 2003Current
The clinical effectiveness and cost effectiveness of insulin pump therapy
NICE TA57
—Optimised Not recommended26 Feb 2003Current
Guidance on the use of vinorelbine for the treatment of advanced breast cancer
NICE TA54
VinorelbineNot recommended Recommended13 Dec 2002Current
Guidance on the use of ultrasound locating devices for placing central venous catheters
NICE TA49
—Not recommended Optimised4 Oct 2002Current
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma
NICE TA37
RituximabOnly in research Not recommended27 Mar 2002Current
The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer
NICE TA33
Irinotecan, Oxaliplatin, RaltitrexedNot recommended Recommended Optimised Only in research27 Mar 2002Replaced by TA93
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
NICE TA32
—Not recommended23 Jan 2002Current
Taxanes for the treatment of breast cancer
NICE TA30
Docetaxel, PaclitaxelNot recommended Recommended26 Sep 2001Replaced
Guidance on the use of gemcitabine for the treatment of pancreatic cancer
NICE TA25
GemcitabineRecommended Not recommended8 May 2001Replaced
Hearing disability - hearing aids
NICE TA8
—Not recommended Recommended23 Jul 2000Withdrawn

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.